ReviewHematological oncology2025
Multiple Myeloma Unpacked.
Review in Hematological oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- CD56 negativity is associated with worse survival outcomes in patients with multiple myeloma: a meta-analysis.World journal of surgical oncology · 2026Pooled it
- Anti-BCMA CAR-NK Cells Reveal Enhanced Cytolytic and Secretory Responses Against Myeloma Cells.APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2026Article
- Extracellular Vesicles as Master Regulators of Immune Modulation in Multiple Myeloma.International journal of molecular sciences · 2026Review
- Identification of exhausted CD8Translational cancer research · 2026Article
- Influence ofBiomedicines · 2026Article
- Real-world treatment patterns and outcomes of patients with multiple myeloma initiating elranatamab: results from the ALTITUDE-1 and ALTITUDE-2 retrospective cohort studies.Future oncology (London, England) · 2026Observational
- Ocular Manifestations Associated with Hematologic Malignancies: Mechanisms, Diagnosis, and Management.Medical sciences (Basel, Switzerland) · 2026Review
- Integrating Bidirectional Mendelian Randomization with Multi-Omics Reveals Causal Serum Metabolites and Novel Metabolic Drivers of Multiple Myeloma.International journal of molecular sciences · 2026Article
- miR-142-5p promotes TSCM differentiation and suppresses progressive T-cell maturation via targeting PRKCB.Frontiers in immunology · 2026Article
- Cryopreserved versus Fresh Stem Cell Grafts in Autologous Transplantation for Multiple Myeloma: Impact on Early Toxicity and Engraftment.Journal of blood medicine · 2026Article
- From toxicity to immunity: Evaluating CAR-T and conventional therapies in multiple myeloma through quality-adjusted life year (QALY) outcomes.Therapeutic advances in hematology · 2026Review
- RNF25 serves as a novel diagnostic and prognostic biomarker in multiple myeloma: a multi-cohort integrative analysis.Hereditas · 2025Article
- Efficacy and Safety of Newly Diagnosed Multiple Myeloma Combination Therapies: A Systematic Review Integrating Network Meta-Analysis and Real-World Vigilance Study.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Targeting the MEK/ERK Pathway to Suppress P-Glycoprotein and Reverse Carfilzomib Resistance in Multiple Myeloma.International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple myeloma (MM) is a hematologic malignancy characterized by the clonal proliferation of plasma cells in the bone marrow. The current treatment landscape for multiple myeloma involves a combination of proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, and autologous stem cell transplantation, which have significantly improved survival outcomes in recent years. However, the disease remains challenging, particularly in relapsed and refractory cases. Ongoing clinical trials are evaluating new therapeutic options, including chimeric antigen receptor T cell therapy, bispecific antibodies, antibody drug conjugate and novel agents like Cereblon E3 Ligase Modulatory Drugs. This review summarizes the key diagnostic criteria, prognostic features, response assessment for MM and highlights the current treatment landscape.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.